Association of the Charcot–Marie–Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance)

Journal of the Neurological Sciences

Volumn 357, Issue 1-2, 2015, Pages 35-40

  Boora, Ganesh K ^a   Kulkarni, Amit A ^a   Kanwar, Rahul ^a   Beyerlein, Peter ^b   Qin, Rui ^a   Banck, Michaela S ^a   Ruddy, Kathryn J ^a   Pleticha, Josef ^a   Lynch, Cynthia A ^c   Behrens, Robert J ^d   Züchner, Stephan ^e   Loprinzi, Charles L ^a   Beutler, Andreas S ^a  

^a MAYO CLINIC   (United States)

^b Technische und forschende Hochschule Wildau   (Germany)

^c GUTHRIE RESEARCH INSTITUTE   (United States)

^d Iowa Oncology Research Association Community Clinical Oncology Program   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; ARHGEF10 PROTEIN, HUMAN; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR;

ADULT; ARHGEF10 GENE; ARTICLE; CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE; HEREDITARY MOTOR SENSORY NEUROPATHY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BIOLOGICAL MODEL; CASE CONTROL STUDY; CHEMICALLY INDUCED; GENETICS; MUTATION; PERIPHERAL NEUROPATHY; PHARMACOGENETICS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CASE-CONTROL STUDIES; CHARCOT-MARIE-TOOTH DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MODELS, GENETIC; MUTATION; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS;

EID: 84934324585     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2015.06.056     Document Type: Article

References (20)

1. Klein, C.J., Duan, X., Shy, M.E., Inherited neuropathies: clinical overview and update. Muscle Nerve 48 (2013), 604–622, 10.1002/mus.23775.
2. Saporta, A.S.D., Sottile, S.L., Miller, L.J., et al. Charcot–Marie–Tooth disease subtypes and genetic testing strategies. Ann. Neurol. 69 (2011), 22–33, 10.1002/ana.22166.
3. Züchner, S., Vance, J.M., Mechanisms of disease: a molecular genetic update on hereditary axonal neuropathies. Nat. Clin. Pract. Neurol. 2 (2006), 45–53, 10.1038/ncpneuro0071.
4. Timmerman, V., Strickland, A.V., Züchner, S., Genetics of Charcot–Marie–Tooth (CMT) Disease within the Frame of the Human Genome Project Success. Genes (Basel) 5 (2014), 13–32, 10.3390/genes5010013.
5. Goldstein, D.B., Allen, A., Keebler, J., et al. Sequencing studies in human genetics: design and interpretation. Nat. Rev. Genet. 14 (2013), 460–470, 10.1038/nrg3455.
6. Morrison, A.C., Voorman, A., Johnson, A.D., et al. Whole-genome sequence-based analysis of high-density lipoprotein cholesterol. Nat. Genet. 45 (2013), 899–901, 10.1038/ng.2671.
7. Beutler, A.S., Kulkarni, A.A., Kanwar, R., et al. Sequencing of Charcot–Marie–Tooth disease genes in a toxic polyneuropathy. Ann. Neurol. 76 (2014), 727–737, 10.1002/ana.24265.
8. Schneider, B.P., Li, L., Miller, K., et al. Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. ASCO Meet Abstr, 29, 2011, 1000.
9. Bergmann, T.K., Vach, W., Feddersen, S., et al. GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta Oncol. 52 (2013), 871–874, 10.3109/0284186X.2012.707787.
10. Kulkarni, A.A., Boora, G., Kanwar, R., et al. RWDD3 and TECTA variants not linked to paclitaxel induced peripheral neuropathy in North American trial Alliance N08C1. Acta Oncol., 1–3, 2014, 10.3109/0284186X.2014.985388.
11. Wheeler, H.E., Maitland, M.L., Dolan, M.E., et al. Cancer pharmacogenomics: strategies and challenges. Nat. Rev. Genet. 14 (2013), 23–34, 10.1038/nrg3352.
12. Postma, T.J., Aaronson, N.K., Heimans, J.J., et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur. J. Cancer 41 (2005), 1135–1139, 10.1016/j.ejca.2005.02.012.
13. Lavoie Smith, E.M., Barton, D.L., Qin, R., et al. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual. Life Res. 22 (2013), 2787–2799, 10.1007/s11136-013-0379-8.
14. Cavaletti, G., Cornblath, D.R., Merkies, I.S.J., et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann. Oncol. 24 (2013), 454–462, 10.1093/annonc/mds329.
15. Alberti, P., Rossi, E., Cornblath, D.R., et al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann. Oncol. 25 (2014), 257–264, 10.1093/annonc/mdt409.
16. Leal, A.D., Qin, R., Atherton, P.J., et al. North Central Cancer Treatment Group/Alliance trial N08CA — the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120 (2014), 1890–1897, 10.1002/cncr.28654.
17. Neale, B.M., Rivas, M.A., Voight, B.F., et al. Testing for an unusual distribution of rare variants. PLoS Genet., 7, 2011, e1001322, 10.1371/journal.pgen.1001322.
18. PLINK/SEQ genetics library. https://atgu.mgh.harvard.edu/plinkseq/. Accessed 22 Feb 2015.
19. Verhoeven, K., De Jonghe, P., Van de Putte, T., et al. Slowed conduction and thin myelination of peripheral nerves associated with mutant rho Guanine-nucleotide exchange factor 10. Am. J. Hum. Genet. 73 (2003), 926–932, 10.1086/378159.
20. Cavaletti, G., Zanna, C., Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur. J. Cancer 38 (2002), 1832–1837.